Cellectar Biosciences Inc (NAS:CLRB)

Q1 2026 Cellectar Biosciences Inc Earnings Call Transcript

May 14, 2026 / 12:30 PM GMT

Release Date Price: $3.2 (+8.84%)

Transcript 8-K10-Q

Key Points

Positve

Cellectar Biosciences Inc (CLRB) reported positive 12-month follow-on data from the Phase IIb Clover-WAM study, demonstrating durable and consistent responses in heavily pretreated WM patients.
The company plans to file for accelerated FDA approval and initiate a Phase III confirmatory trial for iapopicine, indicating strong confidence in its clinical profile.
Cellectar Biosciences Inc (CLRB) completed an oversubscribed financing round of up to $140 million, significantly strengthening its balance sheet.
The company is advancing its broader pipeline, including the Phase 1B trial of CLR125 for triple-negative breast cancer, showcasing its commitment to expanding its radiopharmaceutical portfolio.
The company has aligned with the FDA on the comparator arm for the Phase III study, demonstrating proactive regulatory engagement.

Negative

Cellectar Biosciences Inc (CLRB) reported a net loss of $5.7 million for the first quarter of 2026, indicating ongoing financial challenges.
Research and development expenses decreased slightly, but the company still faces significant costs associated with clinical trials and manufacturing.
The company's cash and cash equivalents decreased to $8.3 million by the end of the first quarter, highlighting the need for continued financial management.
The Phase III confirmatory trial for iapopicine is not expected to initiate until late 2026, potentially delaying market entry and revenue generation.
The company faces uncertainties related to the successful achievement of milestones tied to the $140 million financing, which could impact future funding.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CLRB.OQ - Cellectar Biosciences Inc
Q1 2026 Cellectar Biosciences Inc Earnings Call
May 14, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session. Please be advised that today's conference call may be recorded. I would now like to hand the conference call over to Anne-Marie Fields, Managing Director at Precision AQ. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Vanessa. Good morning, and welcome to Selectar Bioscience's First Quarter 2026 Financial Results and Business Update Conference Call.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.